AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03624413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care transition from pediatric to adult care for HIV.
Study NCT04781595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon
Description: A single dose of watermelon powder containing 3g of L-citrulline
Study NCT04781595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot
Description: A single dose of beetroot powder containing 8 mmol of nitrate
Study NCT04781595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Watermelon + beetroot
Description: A single dose of watermelon and beetroot powder containing 3g of L-citrulline and 8 mmol of nitrate
Study NCT04781595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of maltodextrin
Study NCT06357910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2303
Description: Take 1 tablet once per period
Study NCT06357910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2302
Description: Take 1 tablet once per period
Study NCT06357910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take 1 tablet once per period
Study NCT04330768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF pulp capping
Description: PRF is injected in the site of exposure
Study NCT04330768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulp capping
Description: conventional pulp capping procedure
Study NCT04573803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin Sodium
Description: Dosing will be as prescribed clinically by the treating physician. Phenytoin Sodium may be administered orally, intravenously or via nasogastric tube.
Study NCT04573803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing will be as prescribed clinically by the treating physician.Levetiracetam may be administered orally, intravenously or via nasogastric tube.
Study NCT05380791 — intervention group
Intervention type: OTHER
Intervention: Follow-up visits
Description: Regular follow-up visits to record information about the patient's surgery and routine post-operative examinations
Study NCT05287282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECAR application
Description: Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
Study NCT05287282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TECAR application
Description: Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
Study NCT06261775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Red meat-based meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
Study NCT06261775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red meat-based meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
Study NCT06261775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lacto-ovo-vegetarian meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
Study NCT06261775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian meal
Description: Participants were provided with food as part of a meal plan. The research team provided all foods and snacks for the intervention.
Study NCT04792554 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive tests and blood taking
Description: Battery of neurocognitive tests and questionnaires including MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, Global Physical Activity Questionnaire, Brief Pain Index, Brief Psychiatric Rating Scale, NuDESC, 3D-CAM. Blood taking.
Study NCT06427486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parents Telecoaching Intervention
Description: - Synchronous (Zoom platform) and Asynchronous coaching sessions for parents of children with autism.
Study NCT04695990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wenyang Huoxue Decoction
Description: Wenyang Huoxue granules
Study NCT05136092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cohort 1: HFCS (fructose) fed
Description: Two to three hours before surgery. Subjects will prepare the sugar solutions (Fructose-containing solution: 250 mL of water containing 41.25 g of D-Fructose and 33.75 g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml
Study NCT05136092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cohort 2: D-Xylose (xylose-fed)
Description: Two to three hours before surgery.~Subjects will prepare the sugar solutions (Xylose-containing solution: 250 mL of water containing 41.25 g of D-Xylose and 33.75g of D-Glucose) by adding 250 ml water to the sugar powder provided by the study team and drink it between two and three hours before surgery.~Samples collected before surgery:~* Blood sample of 5 ml~* Urine Samples 5 ml~Day of Surgery The anesthesia and surgical procedure will undergo as per regular care. Samples collection at the time the surgical specimen is removed~* Blood sample of 5 ml blood will be obtained from the IV line~* Tissue samples~  * 2 Tumor tissue samples 5mmx5mmx5mm,~ * 2 Intestinal /colon tissue samples 5mmx5mmx5mm~ * 2 tissue samples from mesentery tissue 5mmx5mmx5mm~* Optional Liver Biopsy - a 3-5 mm liver tissue will be obtained for research.~* Urine Samples 5 ml
Study NCT06070688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV® biomarker test
Description: one purple top tube of whole blood (2-3 cc) to be used for the MeMed Key® device processing without the need for centrifuge. The MeMed BV® test takes approximately 15 minutes to process and result. After, the sample has been processed and the MeMed BV® test has resulted, the sample of blood will be discarded for each patient enrolled in the study.
Study NCT06070688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
Study NCT06070688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes diagnostic hematology, chemistry, biomarkers, and culture results along with imaging, consults, and medications, in the treatment of acute viral and/or bacterial illness.
Study NCT05761834 — intervention group
Intervention type: OTHER
Intervention: Sample blood and 2D-echocardiography with Doppler
Description: Investigate whether patients with FD and HCM have a different inflammatory phenotype defined by plasma biomarkers, serum proteomic profile and transcriptomic analysis in peripheral blood mononuclear cells.
Study NCT04429230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial pulsed current stimulation (tPCS)
Description: Active tPCS will be delivered through a pair of saline soaked (0.9% NaCl) surface sponge electrodes. Anodal stimulation will be given to brain area based on qEEG findings
Study NCT04429230 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial pulsed current stimulation (tPCS)
Description: Electrode placement will be the same as active stimulation but the electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study NCT06373744 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide , methotrexate , vinorelbine ,capecitabine
Description: The drugs used in metronomic chemotherapy are cyclophosphamide (CTX), methotrexate (M), vinorelbine (VNR), and capecitabine
Study NCT06449300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise-LVT
Description: (low volume training - 3 sessions of 12 exercises per week)
Study NCT06449300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise-MVT
Description: (moderate volume training - 4 sessions of 12 exercises per week)
Study NCT06449300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise-HVT
Description: (high volume training - 5 sessions of 12 exercises per week)
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome injection
Description: 50 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 60 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2400 mg/m² continuous IV infusion in 46 h
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2400 mg/m² continuous IV infusion in 46 h
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m² on Day 1 of a 14-day cycle
Study NCT06259058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 30Gy/5Fx
Study NCT05787912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
Study NCT05787912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid after photobiomodulation
Description: The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
Study NCT04695990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wenyang Huoxue placebo
Description: Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
Study NCT06179550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06179550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT05817630 — intervention group
Intervention type: OTHER
Intervention: Silicone oil Tamponade for Retinal Detachment
Description: eyes with Rhegmatogenous Retinal Detachment (RRD, for whom pars plana vitrectomy and silicone oil had been performed
Study NCT04647383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study NCT04647383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study NCT04647383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study NCT04647383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study NCT05376618 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05143203 — intervention group
Intervention type: OTHER
Intervention: Self-hypnosis training
Description: Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
Study NCT05501249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Integrated Cognitive Motor Training
Description: Aquatic exercise class with focus on cognitive and physical exercise
Study NCT05197829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
Study NCT05197829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care Coordination
Description: All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
Study NCT05197829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
Study NCT05021913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DKL crosslinked sodium hyaluronate 23
Description: is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
Study NCT05021913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Volift™ with lidocaine (Allergan, Inc)
Description: is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
Study NCT04882137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education plus Coaching
Description: Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
Study NCT06004622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calgary Family Intervention Model
Description: under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
Study NCT05333926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHNA-001
Description: 3-month digital therapy program designed to reduce the severity of IBS symptoms
Study NCT06555380 — intervention group
Intervention type: BEHAVIORAL
Intervention: The one-year intervention
Description: A multifactorial family-centered lifestyle intervention with a maximum duration of one year, corresponding to three-four visits. Participants were offered complimentary weekly supervised physical activity. The day-to-day intervention was managed by specialized nurses at local healthcare centers, at the participants' homes, or in a local clinic.
Study NCT06555380 — intervention group
Intervention type: BEHAVIORAL
Intervention: The three-year intervention
Description: A multifactorial family-centered lifestyle intervention extending up to three years, with clinical visits at local healthcare centers which included repeatedly visits (up to 8 times / year). The intervention was managed by specialized nurses.
Study NCT05888584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research readiness tool
Description: Online/paper based tool for use by nurses to aid discussions with lung cancer patients about clinical trials opportunities.
Study NCT04258358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASCADE ways of working
Description: Technology, learning and development resources and nursing and therapeutic care are the key drivers for the CASCADE ways of working promoting community integrated dementia care and support to optimise safety and independence for people living with dementia.
Study NCT05622786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGT - physical rehab
Description: High Intensity Gait Training using treadmill and overhead harness for fall prevention
Study NCT05622786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity physical therapy
Description: Low Intensity Gait Activities
Study NCT05862363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microbiota-directed balanced energy protein (MD-BEP)
Description: Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
Study NCT05862363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)
Description: RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
Study NCT05862363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Description: Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.